Shionogi & Co. Ltd. (4507.TO) Osaka 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y99.78 bln Y97.59 bln Operating Profit Y35.10 bln Y28.11 bln Pretax Profit Y46.33 bln Y36.53 bln Net Profit Y39.36 ...

Shionogi & Co ( ($SGIOF) ) has released its Q1 earnings. Here is a breakdown of the information Shionogi & Co presented to its investors. Shionogi ...

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) today announced that it has successfully completed its previously announced acquisition of ...

Wastewater surveillance at treatment plants offers a low-cost, early warning method for detecting COVID-19. Researchers in Japan conducted an economic evaluation of a system for long-term care ...

Stibo Systems will continue to strengthen their collaboration to further evolve and expand MDM capabilities, supporting Shionogi's sustainable growth and global digital transformation.

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads from the former’s BV500 programme into clinical candidates.

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...

Shionogi & Co ( ($JP:4507) ) just unveiled an update. Shionogi & Co., Ltd. announced that ViiV Healthcare presented results from the VOLITION ...

Transition of promotional activities for allergen immunotherapy drug ACTAIR® in JapanBAAR, Switzerland & OSAKA, Japan & TOKYO-- (BUSINESS WIRE)-- Stallergenes Greer, Shionogi & Co., Ltd ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

The Proteus Syndrome market is entering a pivotal decade, driven by increasing disease recognition, improving diagnostic techniques, development of genetic testing techniques and other innovative ...

LunAIRo, Apnimed's second Phase 3 trial of AD109, met its primary endpoint, demonstrating a reduction in the Apnea-Hypopnea Index (AHI) f ...